CTOR (Citius Oncology) Buildings And Improvements : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Buildings And Improvements?

Citius Oncology Buildings And Improvements Historical Data

The historical data trend for Citius Oncology's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Buildings And Improvements Chart

Citius Oncology Annual Data

Trend

Sep22

Buildings And Improvements

Citius Oncology Semi-Annual Data
	Sep22	Sep23
Buildings And Improvements	-	-

Citius Oncology Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.